Bharat Biotech’s Covaxin gets drug regulator approval for 6-12 year olds

The Drugs Controller General of India (DCGI) has given Bharat Biotech’s Covid vaccine Covaxin restricted emergency use authorisation for children between the age of 6-12 years. Cadila Health’s ZyCoV-D has received restricted emergency use authorisation for children above the age of 12 years of age.

ET had reported that the subject expert committee ( SEC) of the Drugs Controller General of India recommended the use of Bharat Biotech’s Covaxin among children aged 6-12 years amid an uptick in cases in schools. Covaxin, one of the main vaccines administered to adults, is currently being administered to children in the age group of 15-18 years.

The focus has shifted to children’s vaccines amid a fresh surge in Covid-19 cases, especially among children. On Thursday, the SEC also recommended the use of Biological E’s Corbevax among children aged 5-12 years. Corbevax is currently being administered to children in the age group 12-14 years.

Post Settings

By suparna

Leave a Reply